BioLineRx to Announce Results of Phase II/III Trial for BL-1020 During Week of March 18, 2013

News   Jan 08, 2013

 
BioLineRx to Announce Results of Phase II/III Trial for BL-1020 During Week of March 18, 2013
 
 
 

RELATED ARTICLES

Agent Reverses Resistance to Targeted Drug in Some Leukemias

News

After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.

READ MORE

Immune Response Restored in Patients with Melanoma Thanks to New Compound

News

A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.

READ MORE

Zika Vaccine Trials Provide Promising Results

News

Researchers report that an investigational Zika vaccine was well-tolerated and stimulated potentially protective immune responses in three Phase 1 clinical trials,

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE